Recipharm RECI B
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
No direct position possible; monitor IPO/exit 2026–2028 or indirect via EQT.
The EQT takeover bid in August 2026 shifts the investment case to a bid-premium situation for a previously privately held company.
Sentiment has improved slightly as the US investment signals demand and strategic focus within biologics/ATMP, yet visibility in market data and social media remains low because the company is privately held.
NEUTRAL is the call. Positive is the market mood. Medium risk means some things can go wrong.
About the company
Recipharm is a CDMO providing pharmaceutical development and manufacturing services to pharma and biotech customers, with strengths in oral solid dose and sterile fill & finish. The company is privately owned (EQT) and delisted, meaning the shares are not publicly tradable. Latest available full-year information points to record 2024 revenue and continued portfolio focus plus investments in higher-margin capabilities.
Bull case
The EQT takeover bid creates potential for bid premium and exit opportunities.
Bear case
Limited transparency as a privately held company persists despite the bid and increases uncertainty around execution.
Why this signal
The EQT takeover bid in August 2026 shifts the investment case to a bid-premium situation for a previously privately held company.
Recent news
Fitch Ratings published an update on 9 September 2026 of Recipharm Holding GmbH’s credit profile, highlighting high leverage partially offset by a strong CDMO market position and defensive demand.